Repligen Co. (NASDAQ:RGEN) Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC lowered its position in Repligen Co. (NASDAQ:RGEN) by 0.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 940,710 shares of the biotechnology company’s stock after selling 6,167 shares during the period. Repligen makes up about 1.9% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its 21st biggest position. Conestoga Capital Advisors LLC’s holdings in Repligen were worth $139,996,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. New York State Common Retirement Fund boosted its stake in shares of Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after acquiring an additional 71,274 shares during the last quarter. Stephens Inc. AR grew its stake in shares of Repligen by 3.7% during the 3rd quarter. Stephens Inc. AR now owns 46,700 shares of the biotechnology company’s stock valued at $6,950,000 after buying an additional 1,680 shares during the period. Congress Asset Management Co. grew its position in Repligen by 10.5% during the third quarter. Congress Asset Management Co. now owns 103,764 shares of the biotechnology company’s stock valued at $15,442,000 after acquiring an additional 9,842 shares during the period. Diversify Wealth Management LLC lifted its position in Repligen by 19.0% during the third quarter. Diversify Wealth Management LLC now owns 1,919 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 307 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Repligen by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,044 shares of the biotechnology company’s stock worth $899,000 after acquiring an additional 410 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Performance

RGEN stock traded up $2.79 on Friday, reaching $137.06. The company’s stock had a trading volume of 100,931 shares, compared to its average volume of 657,593. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a market capitalization of $7.68 billion, a P/E ratio of -3,355.91, a price-to-earnings-growth ratio of 3.92 and a beta of 0.95. The firm has a fifty day moving average of $142.20 and a two-hundred day moving average of $146.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same quarter last year, the business earned $0.53 earnings per share. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. As a group, analysts predict that Repligen Co. will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RGEN. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, UBS Group lowered their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.